PDS Biotechnology shares slumped about 67% on Tuesday after the company said it would stop internal funding for the Phase 3 VERSATILE-003 trial of PDS0101 and redirect resources to PDS0301, its investigational tumor-targeted interleukin-12 immunocytokine for metastatic colorectal cancer. The company plans to pursue strategic partnerships or other externally funded options for PDS0101 while advancing PDS0301 into a randomized Phase 2b study designed with FDA feedback in mind. Chief Executive Officer and Director Frank Bedu-Addo, Ph.D., said the shift reflects capital discipline and the view that PDS0301 offers a more attractive long-term value opportunity, while the Phase 2 results for PDS0101 could support a partnering strategy. PDS Biotech has highlighted Phase 2 metastatic colorectal cancer data generated with the National Cancer Institute showing a 71% objective response rate at 6 months and an 80% 24-month survival rate in patients with metastatic microsatellite stable and mismatch repair-proficient colorectal cancer with liver metastases, alongside safety observed in more than 380 treated patients. The selloff pushed the stock to a new 52-week low; Benzinga Pro data showed the shares were down 64.01% to $0.26 at publication, and technical indicators cited in the report showed the stock trading around $0.24 with an RSI of 17.90 after a death cross in August.